台灣臨床試驗主持人資料庫|TPIDB

2017-05-01 - 2020-03-04

Phase II

A randomized, double blind, placebo controlled multicenter Phase 2 doseranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjögren’s syndrome

Condition/Disease

Sjögren’s syndrome
Test Drug

VAY736

Participate Sites
7Sites

Terminated5Sites

藍忠亮

China Medical University Hospital

藍忠亮

China Medical University Hospital-Taipei

未分科

2013-09-10 - 2015-10-31

Phase III

A 52-week treatment, multi-center, randomized, doubleblind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD

Condition/Disease

moderate to very severe COPD
Test Drug

QVA149

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

徐武輝

China Medical University Hospital

Division of Thoracic Medicine

2019-09-01 - 2022-12-17

Phase II

An adaptive Phase 2 randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of multiple LOU064 doses in patients with moderate to severe Sjögren’s Syndrome (LOUiSSe)

Condition/Disease

Sjögren’s Syndrome
Test Drug

LOU064

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

藍忠亮

China Medical University Hospital

2020-09-01 - 2023-09-20

Phase I

A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Condition/Disease

Advanced Solid Tumors
Test Drug

ASP1951

Participate Sites
3Sites

Recruiting3Sites

邱昌芳

China Medical University Hospital

Division of Hematology & Oncology

2020-09-20 - 2024-02-22

Phase I

A Phase I, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-866/OBI-821, a Novel Anti-Stage-Specific Embryonic Antigen-4 (SSEA-4) Active Immunotherapy, in Patients with Advanced/Metastatic Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung

Condition/Disease

Cancers of the Ovary, Kidney, Brain, Pancreas, Breast or Lung
Test Drug

OBI-866 (SSEA-4) / OBI-821 (adjuvant)

Participate Sites
2Sites

Recruiting2Sites

白禮源

China Medical University Hospital

Division of Hematology & Oncology

2014-07-01 - 2015-12-31

Phase III

A Phase 3 Study of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Genotype 1 (UNITY 4)

Condition/Disease

Chronic Hepatitis C Genotype 1
Test Drug

Daclatasvir/Asunaprevir/BMS-791325; Film coated tablet; 30 mg/200 mg/75 mg (as the free base)

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

彭成元

China Medical University Hospital

Digestive System Department

2016-11-16 - 2020-01-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD).

Condition/Disease

neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD)
Test Drug

SA237

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

郭育呈

China Medical University Hospital

Division of Neurology

2014-02-01 - 2021-12-31

Phase III

A MULTICENTER, RANDOMIZED, ADDITION TO BASELINE TREATMENT, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SA237 IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NMO SPECTRUM DISORDER (NMOSD)

Condition/Disease

NEUROMYELITIS OPTICA (NMO) AND NMO SPECTRUM DISORDER (NMOSD)
Test Drug

SA237

Participate Sites
5Sites

Terminated5Sites

郭育呈

China Medical University Hospital

Division of Neurology

2014-06-30 - 2017-06-30

Phase III

Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level

Condition/Disease

COPD
Test Drug

Mepolizumab

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

徐武輝

China Medical University Hospital

Division of General Internal Medicine

2019-08-20 - 2021-08-02

Phase I

A phase I, open label study to evaluate the safety and to explore efficacy of allogeneic umbilical cord mesenchymal stem cells in patients with ST-elevation acute myocardial infarction

Condition/Disease

Acute Myocardial Infarction
Test Drug

UMSC01

Participate Sites
1Sites

Recruiting1Sites

蕭連城

China Medical University Hospital

Division of Cardiovascular Diseases

Search Result

List